ARCA biopharma, Inc. (NasdaqCM:ABIO) is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options. In April 2022, the Board of Directors established a Special Committee and, in May 2022, retained Ladenburg Thalmann & Co. Inc. (?Ladenburg?) to evaluate strategic options, including transactions involving a merger, sale of all or part of the Company?s assets, or other alternatives with the goal of maximizing stockholder value.

The Company and Ladenburg have reviewed several potential strategic transactions and continue to evaluate further potential development of the Company?s existing assets, in order to maximize stockholder value. The Company does not have a defined timeline for the strategic review process and the review may not result in any specific action or transaction.